Unlearn
PrivateLast Round
Series C
Feb 8, 2024
Est. Valuation
$265M
Total Funding Raised
$142.05M
Company Overview
Unlearn is a healthcare technology company that develops an AI platform creating digital twins of clinical trial participants to enable smaller, faster, and more successful studies.
Sector
Healthcare & Life Sciences
Verticals
Clinical Trials, Medical AI, Synthetic Data, Healthcare Analytics
Business Model
B2B
Customer Profile
Usage-Based SaaS, Subscription SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Unlearn Comparables
Compare Unlearn with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| QuantHealth | 84% | |
| Nova In Silico | 74% | |
| InSilicoTrials Technologies | 73% |
Unlearn Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Feb 8, 2024 | ||||
| Early Funding | Mar 22, 2023 | ||||
| Series B | Apr 19, 2022 | ||||
| Series A Extension | Nov 5, 2020 | ||||
| Series A | Apr 20, 2020 | ||||
Seed | Jul 12, 2019 |
Key People
Founding team and executive leadership
Unlearn Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Human Capital | Series B |
| DCVC Bio | Series A, Series C, Series B, Seed |
| Founders Fund | Series A, Series B |
| Global Ventures | Series B |
| Necessary Ventures | Series C |
| EPIC Ventures | Series A, Series C, Series A Extension |
| Mubadala Capital | Seed, Series A, Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 13, 2026
Announced the release of AD DTG 4.2, an Alzheimer's disease Digital Twin Generator update.
- Feb 12, 2026
Partnering with VectorY Therapeutics for PIONEER-ALS study using digital twins.
Recent news
Latest coverage and updates
- partners_withJul 9, 2026
Unlearn.ai, Inc. partnered with Acumen Pharmaceuticals, Inc. on Jul 9th '26.
Unlearn Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Unlearn's valuation, stock price, and market status.
Is Unlearn a public or private company?
Unlearn is a private company.
What is the current stock price of Unlearn?
Unlearn is a private company with no public stock price. No recent secondary market data is available.
How much is Unlearn worth (valuation)?
Unlearn's valuation is estimated at $265.0M based on funding round data.
Can I buy Unlearn stock?
Unlearn shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Unlearn's last funding round?
Unlearn's most recent funding round was Series C on March 21, 2023.
Who are the main investors in Unlearn?
Key investors in Unlearn include DCVC Bio, Global Ventures, EPIC Ventures, Wittington Ventures, 8VC.
Will Unlearn IPO soon?
No public IPO plans have been announced for Unlearn.
How can I track Unlearn secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Unlearn's secondary market activity and sign up for updates.